nach oben

International Urogynecology Journal

Erschienen in:

01.03.2007 | Current Opinion/Update

Bias in research and conflict of interest: why should we care?

verfasst von: H. P. Dietz

Erschienen in: International Urogynecology Journal | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Excerpt

Medical journals are a prime source of professional information for doctors and have a major impact on patient care. Editors and authors are, even more so than the practising clinician, trustees of the public good. Our role is to provide information that is as ‘true’ as we can make it. To this purpose, it is imperative that bias in published research be reduced as far as possible. In fact, “the entire infrastructure of science [...] is built on the fundamental notion of eliminating, or at least controlling for, [...] bias” [1]. In therapeutic medicine, the double-blind multicentre randomised controlled trial (RCT) is seen as the ‘gold standard’ of bias reduction—developed in response to higher scientific and regulatory standards and to fulfil the precepts of evidence-based medicine. …

Coyle SL (2002) Ethics, Human Rights Committee ACoP-A. Physician-industry relations. Part 1: individual physicians. Ann Intern Med 136(5):396–402PubMed

Korn DMD (2002) Industry, academia, investigator: managing the relationships. Acad Med 77(11):1089–1095 (November)PubMedCrossRef

Mathews W (2005) A ghost story: at medical journals, writers paid by industry play big role. Wall Street J A1 (Dec 13)

Kassirer J (2006) Physicians on the take. MedGenMed 8(1):74PubMed

Bhandari M, Busse JW, Jackowski D et al (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials (see comment). CMAJ Can Med Assoc J 170(4):477–480

Montgomery JH, Byerly M, Carmody T et al (2004) An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 25(6):598–612PubMedCrossRef

Buchkowsky SS, Jewesson PJ (2004) Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38(4):579–585PubMedCrossRef

Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatr 162(10):1957–1960PubMedCrossRef

Goetzsche P (2005) Research integrity and pharmaceutical industry sponsorship. Med J Aust 182(11):549

10.

Gibbons R, Landry F, Blouch D et al (1998) A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. J Gen Intern Med 13:151–154PubMedCrossRef

11.

Rogers W, Mansfield P, Braunack-Mayer A, Jureidini J (2004) The ethics of pharmaceutical industry relationships with students. Med J Aust 180:411–414PubMed

12.

Andersen NV (2006) Gunnar lose vs. Yamanouchi. Ugeskrift for Laeger 168(6):546

13.

Brown AJ (2001) Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38(Suppl 5):S3–S19PubMed

14.

Choudhry NK, Stelfox HT, Detsky AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287(5):612–617PubMedCrossRef

15.

Moynihan R (2003) The making of a disease: female sexual dysfunction. Br Med J 326:45–47CrossRef

16.

Moynihan R, Cassels A (2005) Selling sickness: how drug companies are turning us all into patients. G. Allen, Sydney, Australia

17.

N.N. World Association of Medical Editors Recommendations on Publication Ethics Policies for Medical Journals, 2006 at: http://www.wame.org/, accessed 15.5.06

18.

N.N. Uniform Requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication: International Committee of Medical Journal Editors, 2006, at: http://www.icmje.org/, accessed 15.5.06

19.

Korn, D. and S. Ehringhaus, Principles for strengthening the integrity of clinical research. 2006, Public Library of Science at: http://www.plosclinicaltrials.org

20.

N.N. World Medical Association Declaration of Helsinki, 2004, at: http://www.wma.net/e/policy/b3.htm., accessed 15.5.06

21.

4th Annual Patient Recruitment for Clinical Trials. 2006: New York, at: www.marcusevansbb.com/recruitment, accessed 10.6.06

22.

The Allhat Officers and Coordinators for the Allhat Collaborative Research Group. Major outcomes in High-Risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA, 2002(Dec 18): p. 2981CrossRef

23.

Liebermann J, Stroup T, McEvoy J et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–23CrossRef

24.

Angell M (2004) The truth about the drug companies: how they deceive us and what to do about it. Random House, New York

25.

Curfman G, Morrissey S, Drazen J (2006) Expression of concern reaffirmed. N Engl J Med 354(11):1193PubMedCrossRef

26.

Moynihan R (2002) Alosetron: a case study in regulatory capture, or a victory for patients’ rights? Br Med J 325:592–595CrossRef

27.

Lievre M (2002) Alosetron for irritable bowel syndrome. Br Med J 325:555–556CrossRef

28.

Horton R (2001) Lotronex and the FDA: a fatal erosion of integrity. Lancet 357:1544–1545PubMedCrossRef

29.

Fontanarosa PB, Flanagin A, DeAngelis CD (2005) Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA 294:110–111 (July 6)PubMedCrossRef

Kassirer JP (2005) On the take. Oxford University Press, New York

Krimsky S (2003) Science in the private interest. Rowman & Littlefield, Lanham, MD

Angell M (2004) The truth about the drug companies: how they deceive us and what to do about it. Random House, New York

Moynihan R, Cassels A (2005) Selling sickness: how drug companies turning us all into patients. G. Allen, Sydney

Titel: Bias in research and conflict of interest: why should we care?
verfasst von: H. P. Dietz
Publikationsdatum: 01.03.2007
Verlag: Springer-Verlag
Erschienen in: International Urogynecology Journal / Ausgabe 3/2007
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-006-0236-1

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Bias in research and conflict of interest: why should we care?

Excerpt

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Gynäkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

Perioperative complications in abdominal sacrocolpopexy and vaginal sacrospinous ligament fixation procedures

Prevalence of diastasis recti abdominis in a urogynecological patient population

Outcome of transvaginal radiofrequency for treatment of women with stress urinary incontinence

Funneling before and after anti-incontinence surgery—a prognostic indicator? Part 2: tension-free vaginal tape

Incisional hernia after a tension-free vaginal tape procedure

Intermittent urinary retention secondary to a uterine leiomyoma

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Gynäkologie